FDA has granted Breakthrough Therapy designation to Merck’s oral TLR7/8 inhibitor enpatoran for lupus with active cutaneous manifestations, supported by Phase 2 WILLOW results and advancing into the global Phase 3 ELOWEN program.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Merck’s investigational oral therapy enpatoran for the treatment of lupus with active cutaneous manifestations. The designation recognizes preliminary clinical evidence suggesting the therapy may provide a substantial improvement over available treatment options for a serious condition and enables closer collaboration with the FDA to accelerate development and regulatory review.
The designation was supported by findings from the Phase 2 WILLOW study, which showed clinically meaningful improvements in lupus symptoms, particularly among patients with active skin disease. If approved, enpatoran could become the first targeted therapy specifically indicated for lupus patients with active cutaneous manifestations, an area where no approved therapies currently exist.
Targeting a Key Inflammatory Pathway
Enpatoran is an investigational, oral, selective toll-like receptor (TLR) 7 and TLR8 inhibitor. These receptors play a central role in the innate immune pathways that drive inflammation in both cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). By inhibiting TLR7/8 signaling, enpatoran aims to reduce immune activation that contributes to skin lesions while potentially improving systemic manifestations of lupus.
Cutaneous involvement affects an estimated 72% to 85% of people living with lupus and represents the first sign of disease in nearly 29% of cases. Patients often experience persistent photosensitive rashes, scarring, pigment changes, and significant psychosocial burden. Despite available immunosuppressive therapies, many fail to achieve adequate disease control, highlighting the need for more targeted treatment approaches.
Phase 2 WILLOW Findings Supported FDA Decision
The FDA’s decision was based on results from the Phase 2 WILLOW trial (NCT05162586), a multicenter, randomized, double-blind, placebo-controlled, dose-finding study evaluating orally administered enpatoran. The study incorporated an adaptive basket design that enrolled patients with both CLE and SLE, allowing investigators to assess treatment effects across different lupus populations.
According to Merck, enpatoran demonstrated clinically meaningful improvements in lupus disease activity, with the greatest benefit observed in patients with active cutaneous manifestations. While the company did not disclose detailed efficacy or safety results in the announcement, the data were considered sufficient to support Breakthrough Therapy designation.
Merck Advances Global Phase 3 Program
Merck recently initiated the global Phase 3 ELOWEN clinical program, consisting of ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218). The randomized, double-blind, placebo-controlled studies will enroll approximately 200 participants each across 266 sites in 26 countries.
Participants will receive enpatoran or placebo twice daily in addition to standard of care. The primary endpoint is the change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score, with the program also evaluating the relationship between improvements in skin disease and systemic lupus activity.
Regulatory Path Forward
David Weinreich, MD, MBA, Global Head of Research & Development and Chief Medical Officer for Merck’s Healthcare business, said skin manifestations affect the majority of lupus patients and remain associated with substantial physical and psychosocial burden despite limited targeted treatment options. He noted that the FDA designation reflects enpatoran’s potential to address visible skin disease while offering broader clinical benefit and reaffirmed the company’s commitment to working closely with regulators to advance the therapy.
Enpatoran remains investigational and has not been approved for any indication worldwide. The Breakthrough Therapy designation provides important regulatory momentum as Merck advances late-stage development, with the Phase 3 ELOWEN program expected to define the therapy’s role in expanding treatment options for patients with lupus and active cutaneous disease.
Reference
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.